Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19

Not Applicable

• Conditions: Covid19
• Interventions: Diagnostic Test: serology

• Registration Number: NCT04543006
• Lead Sponsor: University Hospital, Grenoble

Brief Summary

Covid-19 is associated with the onset of anti-SARS-CoV-2 antibodies; in a majority of patients, neutralizing antibodies are detected. However, the long-term persistence of such protective antibodies is not known.

The investigators will explore patients with a proven Covid-19 (positive PCR) 6 and 12 months after the diagnosis to determine whether neutralizing antibodies are still detected.

The investigators will determine whether this persistance varies according to

* the severity of the Covid-19

* a treatment by steroids during the covid-19. This will help to anticipate whether a second wave of infection is possible in a non-naive population.

Detailed Description

Covid-19 is associated with the onset of anti-SARS-CoV-2 antibodies; in a majority of patients, neutralizing antibodies are detected. However, the long-term persistence of such protective antibodies is not known.

The investigators will explore adult patients with a proven Covid-19 (positive PCR) 6 and 12 months after the diagnosis to determine whether neutralizing antibodies are still detected.

The investigators will determine whether this persistance varies according to

* the severity of the Covid-19 (3 groups: no oxyegn therapy; oxygen therapy of less than 3L/min; oxygen therapy of 3L/min or more)

* a treatment by steroids during the covid-19. Immunocompromised patients will be excluded.

Study Timeline

• Status Verified: 2020-09
• Study Start: 2020-09-08
• Study First Submitted: 2020-09-08
• Study First Submitted QC: 2020-09-08
• Study First Posted: 2020-09-09
• Last Update Submitted: 2020-09-11
• Last Update Posted: 2020-09-16
• Primary Completion: 2021-09-30
• Study Completion: 2021-12-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 170

Inclusion Criteria

• positive SARS-CoV-2

Exclusion Criteria

• age under 18
• immunocompromised at the onset of Covid-19

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Covid-19	serology	only arm: Covid-19 proven by PCR

Primary Outcome Measures

Name	Time	Method
anti-SARS-CoV-2 neutralizing antibody titers	1 day	Titer in plamsa of neutralizing anti-SARS-CoV-2 antibody